Shenzhen Mindray Bio-medical Electronics Co., Ltd. Class A · SZSE:300760

Shenzhen Mindray Bio-medical Electronics Co., Ltd. Class A — Mindray — H1 2024 Earnings Presentation

18 slides from Shenzhen Mindray Bio-medical Electronics Co., Ltd. Class A's earnings presentation, August 2024

Slide 3: Robust Growth Amidst Challenges
Robust Growth Amidst Challenges Revenue 20.53Billion RMB Net profit attributable to Net operating cash flow YoY growth11.1% shareholders7.56Billion RMB 8.50Billion RMB YoY growth17.4% YoY growth Unit: Billion RMB YoY growth Unit: Billion RMB 89.5% YoY growth Unit: Billion RMB YoY growth 11.1% 20.53
Slide 4: Keep Improving Investor Returns
Keep Improving Investor Returns The Company proposes to distribute a Dividend payout ratio cash dividend of 40.6 RMB for every 10 65.1% 65.1% 60.7% shares to all shareholders 56.8% Proposed a total of 4.92 billion RMB for interim 2022 2023 2024 interim dividends dividends 4 © 2024 深圳迈瑞生物医疗电子股份有限公司版权
Slide 5: Increasing High-end Penetration at International Market and China Market Shows Strong Growth in Consumable Business
Increasing High-end Penetration at International Market and China Market Shows Strong Growth in Consumable Business International Market China Market Revenue7.91 Billion RMB Revenue 12.62 Billion RMB YoY growth 18.1% YoY growth 7.2% Specifically, the IVD segment grew by over 30% Specifically, the IV
Slide 6: In-vitro Diagnostics Leads the Growth
In-vitro Diagnostics Leads the Growth In-vitro Diagnostics (IVD) Medical Imaging System (MIS) Revenue 7.66 Billion RMB Revenue 4.27 Billion RMB YoY growth 28.2% YoY growth 15.5% 37.3% Accounting for Revenue 20.8% 20.8% Accounting for Revenue 30% CLIA business grew by over 37.3% High-end and Premium
Slide 9: Blockbuster Products: Patient Monitoring and Life Support
Blockbuster Products Patient Monitoring and Life Support Segment 4K 3D Endoscope System Laparoscopic staplers Critical Illness Decision Support System 9 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 10: Blockbuster Products: In-vitro Diagnostics
Blockbuster Products In-vitro Diagnostics Segment CL-2600i Chemiluminescence BS-1000M Chemistry M680 Chemistry and Immunoassay Immunoassay System Analyzer Integrated Solution 10 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 11: Blockbuster Products: Medical Imaging System
Blockbuster Products Medical Imaging System Segment Mid to High-end cart-based ultrasound system Mid to High-end cart-based ultrasound Resona/Nuewa I9 Elite Edition system Resona/Nuewa I8 11 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有
Slide 14: Smiles for All
Smiles for All 11 employees joined in the voluntary medical consultation activities in Heze, Shandong, organized by Operation Smile, assisting in screening 93 patients and completing surgeries for 45 patients with cleft lip and palate By June 30, 2024, the Company raised more than 41,000 RMB for the
Slide 15: Promoting Public First Aid
Promoting Public First Aid As of June 30, 2024, Mindray's AEDs have successfully treated 280 cases of cardiac arrest that occurred in public places in China Completed 165 first-aid training sessions in first half of the year, reaching over 6,000 participants Directly or indirectly mobilized 300,000
Slide 16: Rural Revitalization
Rural Revitalization The Chairman, Li Xiting, donated to the Dangshan County wastewater treatment plant expansion project and the Litun Village road construction project, aiming to improve Dangshan's environmental protection capabilities and address infrastructure deficiencies 16 © 2024 深圳迈瑞生物医疗电子股份
Slide 17: 2024H1 Financial Statement
2024H1 Financial Statement Billion RMB 2024H1 2023H1 YoY 2024Q2 2023Q2 YoY Revenue 20.53 18.48 +11.12% 11.16 10.11 +10.35% Gross margin 66.25% 65.60% +0.66pct 66.50% 64.94% +1.56pct Net profit attributable to 7.56 6.44 +17.37% 4.40 3.87 +13.69% shareholders Net margin 36.83% 34.87% +1.96pct 39.44% 3

Mindray — H1 2024 Earnings Presentation on 6ix

Shenzhen Mindray Bio-medical Electronics Co., Ltd. Class A — Mindray — H1 2024 Earnings Presentation

Slide 1: Mindray 2024H1 Results Release and Earnings Call

Slide 2: Operating Highlights

Slide 3: Robust Growth Amidst Challenges

Slide 4: Keep Improving Investor Returns

Slide 5: Increasing High-end Penetration at International Market and China Market Shows Strong Growth in Consumable Business

Slide 6: In-vitro Diagnostics Leads the Growth

Slide 7: Innovation and R&D

Slide 8: Building an Ecosystem through Convergent Innovation

Slide 9: Blockbuster Products: Patient Monitoring and Life Support

Slide 10: Blockbuster Products: In-vitro Diagnostics

Slide 11: Blockbuster Products: Medical Imaging System

Slide 12: Sustainable Development

Slide 13: MSCI ESG Rating: AA

Slide 14: Smiles for All

Slide 15: Promoting Public First Aid

Slide 16: Rural Revitalization

Slide 17: 2024H1 Financial Statement

Slide 18: 18 © 2024 深圳迈瑞生物医疗电子股份有限公司版权所有